ScPharmaceuticals
Infused therapies —bringing them to a better place, a new *sight* of care.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 167 % | 104 % | 81 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (339 %) | (178 %) | (71 %) | (7 %) | 14 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (403 %) | (234 %) | (80 %) | (9 %) | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 87 % | 33 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
scPharmaceuticals is a pharmaceutical company dedicated to developing and commercializing innovative solutions aimed at enhancing outpatient care. The company focuses on creating proprietary subcutaneous furosemide treatments for heart failure (HF) diuresis, delivered via an on-body infusor. This technology allows patients to receive necessary treatments outside of a hospital setting, improving comfort and maintaining dignity during recuperation. scPharmaceuticals primarily serves patients with heart failure, targeting the outpatient care market. The business model revolves around the development and sale of its proprietary drug delivery systems, generating revenue through product sales and potentially through partnerships or licensing agreements. By shifting care from inpatient to outpatient settings, scPharmaceuticals aims to transform disease management and reduce healthcare costs.
Keywords: subcutaneous furosemide, heart failure, outpatient care, on-body infusor, pharmaceutical innovation, HF diuresis, patient comfort, healthcare cost reduction, proprietary treatments, disease management.